A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice.

Affiliation

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. Electronic address: [Email]

Abstract

Despite patient and provider interest, the use of PCSK9i therapy remains limited in clinical practice. High annual listed prices have created intense payer scrutiny and frequent health plan denials, with national approval rates in the range of 30% to 40%.

Keywords

Alirocumab (Praluent),Atherosclerotic cardiovascular disease (ASCVD),Evolocumab (Repatha),Familial hypercholesterolemia (FH),Low-density lipoprotein cholesterol (LDL-C),Prior authorization,